Overview

With each significant achievement, we have made an enduring impression on our path towards becoming a widely respected organisation. Our goal is to be a valuable collaborator for the pharmaceutical industry as they strive to improve people's lives while prioritising our responsibility to impact the communities we serve positively.

  • 2001

    DNPL was formed in Pune.

  • 2003

    Commissioning of Manufacturing Block I and Block II.

  • 2005

    DNPL received its Drug Manufacturing License from MH-FDA for manufacturing APIs.

  • 2010

    Commissioning of Manufacturing Block III.

  • 2011

    Commissioning of Manufacturing Block IV. Files USDMF for 10-DAB III and CEP for Digoxin.

  • 2014

    DNPL achieves successful inspections by both USFDA and CDSCO, ensuring compliance and quality standards.

  • 2016

    DNPL clears USFDA's second and third inspections, successfully undergoes its first EDQM Inspection, and secures EU-GMP certification from Germany.

  • 2017

    CDSCO issues Written Confirmation for the second time.

  • 2018

    DNPL successfully passes its fourth inspection by the USFDA. Received approval of Digoxin DMF from NMPA (China).

  • 2019

    Commissioning of Manufacturing Block V.

  • 2021

    DNPL passes the second EDQM inspection and third CDSCO inspection for Written Confirmation.

  • 2023

    DNPL successfully passes its fifth inspection by the USFDA.